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SUMMARY
The prevalence, incidence and outcomes of haemolytic uraemic syndrome (HUS) and
thrombotic thrombocytopaenic purpura (TTP) are not well established in adults or children from
prospective studies. We sought to identify both outcomes and current management strategies
using prospective, national surveillance of HUS and TTP, from 2003 to 2005 inclusive. We also
investigated the links between these disorders and factors implicated in the aetiology of HUS
and TTP including infections, chemotherapy, and immunosuppression. Most cases of HUS
were caused by verocytotoxin-producing Escherichia coli (VTEC), of which serotype O157
predominated, although other serotypes were identiﬁed. The list of predisposing factors for TTP
was more varied although use of immunosuppressive agents and severe sepsis, were the most
frequent precipitants. The study demonstrates that while diﬀerentiating between HUS and TTP
is sometimes diﬃcult, in most cases the two syndromes have quite diﬀerent predisposing factors
and clinical parameters, enabling clinical and epidemiological proﬁling for these disorders.
INTRODUCTION
Haemolytic uraemic syndrome (HUS) and throm-
botic thrombocytopaenic purpura (TTP) are rare dis-
orders characterized by microangiopathic haemolytic
anaemia, microthrombi, and multi-organ injury.
HUS is one of the most common causes of acute renal
failure in childhood worldwide [1]. Occasionally,
cases may experience long-term renal impairment,
and the determinants of long-term outcomes are
unclear [2, 3]. HUS is a subset of thrombotic micro-
angiopathy that has a number of aetiologies including
several infectious agents, the most common of these
being Escherichia coli O157 [4]. Previous surveillance
of childhood HUS in Scotland identiﬁed E. coli O157
in over 90% of cases [5]. Clinical surveillance is
particularly relevant in Scotland, where consistently
higher rates of infection with E. coli O157 have been
reported than in other parts of the United Kingdom
or Europe (Fig.).
Whereas childhood HUS most often follows
bloody diarrhoea caused by verocytotoxin-producing
E. coli (VTEC), TTP frequently occurs in adults with
a number of possible identiﬁable precipitants. It is
generally accepted that the pathogenesis of TTP
involves an acquired inhibitor, or congenital absence,
of the von Willebrand factor metalloprotease [6, 7].
This protease was recently identiﬁed as a member
of the ADAMTS family, namely ADAMTS13 [8]. In
contrast, patients with VTEC-associated HUS have
normal ADAMTS13 activity [9]. There has been
much debate as to whether TTP and HUS are two
* Author for correspondence : Dr K. G. J. Pollock, Health
Protection Scotland, Clifton House, Clifton Place, Glasgow, UK.
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distinct entities or the same disease along a clinical
spectrum [10–12]. Although the cause of thrombotic
microangiopathy might not be immediately appar-
ent when patients present, the term HUS/TTP is
inexplicit and does not encompass all forms of
thrombotic microangiopathies.
Here, we report a population-based epidemio-
logical surveillance study of thrombotic microangio-
pathies in all age groups, with particular emphasis on
the links between these syndromes and precipitants
of HUS and TTP, including infections, vascular
procedures, and medications [13]. Furthermore, we
sought to identify outcomes and describe manage-
ment strategies by clinicians. Without current sur-
veillance of HUS and TTP, neither incidence nor
outcomes are well established in adults or children.
METHODS
Cases were ascertained prospectively over 3 years of
an active, continuing national surveillance pro-
gramme in 2003. Consultants from six hospitals
throughout Scotland were approached for partici-
pation in the study. Consultants in haematology,
infectious diseases, microbiology, nephrology and
paediatrics were sent fortnightly e-mails with the case
deﬁnition as in Table 1, and asked to indicate whether
they had a ‘case of thrombotic microangiopathy to
report ’ or ‘nil return’. Further information on
possible cases was obtained by telephone including
date of onset, gender, age, hospital and possible
public health implications (e.g. infection with VTEC).
A unique study number was created to maintain sub-
ject anonymity. Questionnaires, information sheets
and consent forms were subsequently sent to the
reporting clinician via post or e-mail. All completed
forms and questionnaires were returned to Health
Protection Scotland (HPS) and the data were entered
into an Epi-Info (Version 6) database (CDC, Atlanta,
GA, USA).
Statistical methods
The statistical signiﬁcances of associations between
categorical variables were investigated using x2 or
Fisher’s exact tests. Normally distributed quantitative
variables were compared using t tests with results
displayed as mean (¡S.E.M.). All analyses were per-
formed using SPSS version 11 (SPSS Inc., Chicago,
IL, USA) with a signiﬁcance level of 5%.
RESULTS
Between 1 January 2003 and 31 December 2005,
110 reports of thrombotic microangiopathy were
provided to HPS, of which 73 were designated by the
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Fig. Incidence of E. coli O157 infection in Scotland compared with England and Northern Ireland (1984 2005). [Data out
with Scotland courtesy of Health Protection Agency: CDSC Northern Ireland and Laboratory of Enteric Pathogens/CDSC
Colindale (E&W).]
reporting clinicians as HUS and 37 as TTP. These
ﬁgures correspond to respective average annual in-
cidences of 0.47 and 0.24 cases per 100 000. Clinicians
also reported three patients with thrombocytopaenia
but there was no renal impairment or neurological
sequelae involved and upon recommendation by the
relevant clinician, it was decided not to include these
as cases of thrombotic microangiopathy. Forty-seven
cases were male, and there was a signiﬁcant associ-
ation between gender and diagnosis of thrombotic
microangiopathy (x2, P=0.021). More males than
expected had HUS and more females than expected
had TTP. There was a signiﬁcant age-related diﬀer-
ence in type of thrombotic microangiopathy with
HUS patients having a mean age of 18 (¡2.6) years
compared with TTP patients having a mean age of
48 (¡3.3) years (x2, P<0.001). Geographical origin
as determined by NHS Board of residence was
investigated as a predisposing factor to which type of
thrombotic microangiopathy developed in the patient
cohort. Rural and urban areas have been deﬁned
elsewhere based on standardized incidence rates (SIR)
for zoonotic infection including E. coli O157 [14].
Rural residents were more likely to be diagnosed with
HUS, while urban residents were more likely to be
diagnosed with TTP (P=0.018).
Predisposing factors for development of thrombotic
microangiopathies
Table 2 demonstrates that, in this survey, illnesses
designated as HUS are primarily associated with
E. coli O157 infection and this association is highly
signiﬁcant (60/73, P<0.001). Other causes of HUS
included VTEC of non-O157 serotype (serotypes
O177, O145 and O-unidentiﬁable, one patient each).
Table 1. Case deﬁnition for thrombotic microangiopathy
Case deﬁnition
Any Scottish resident with evidence of haemolytic uraemic syndrome, thrombotic thrombocytopaenic purpura or other
presentation of thrombotic microangiopathy, comprising :
Microangiopathic haemolytic anaemia (low or falling haemoglobin/fragmented red cells)
AND
Thrombocytopaenia (platelets<150 000 in 109/l)
PLUS
Acute renal impairment, including oligoanuria, elevated plasma creatinine for age (plasma urea>8 mmol/l and creatinine
>140 mM/l) renal impairment was deﬁned as elevated plasma creatinine for age (plasma urea>8 mmol/l and creatinine
>140 mM/l
AND/OR
Acute neurological features (reduced consciousness, seizure, cerebrovascular accident)
Table 2. Predisposing factors in development of haemolytic uraemic syndrome (HUS) or thrombotic
thrombocytopaenic purpura (TTP) – x2 analyses performed on predisposing factors and development of
thrombotic microangiopathy
Predisposing factor HUS (cases) TTP (cases)
Infection with verocytotoxin producing O157 E. coli 60 1
Infection with verocytotoxin producing non O157 E. coli 3 0
Diarrhoea and vomiting (no pathogen identiﬁed) 5 0
Pre existing renal disease 3 6
Relapsing disease 1 1
Parvovirus B19/MMR immunization/SCID 1 0
Tacrolimus treatment for organ transplant 0 6
Pregnancy 0 2
Severe sepsis 0 7
Collagen/vascular disorders 0 14
Total number of cases 73 37
Diarrhoea-positive HUS was also seen in ﬁve
other patients and while no pathogen was identiﬁed,
the symptoms strongly suggested VTEC infection
(bloody diarrhoea and abdominal cramps with
no fever reported). One case of atypical HUS was
reported where the predisposing factors considered
to be clinically signiﬁcant were infection with parvo-
virus B19 and recent immunization with the MMR
vaccine. However, this patient was subsequently
diagnosed as having severe combined immune deﬁc-
iency.
Identiﬁed predisposing factors for a diagnosis of
TTP were more diverse. Unlike HUS, prior E. coli
O157 infection was not signiﬁcantly associated with
TTP, this being identiﬁed in only one case. Moreover,
this patient was on long-term aspirin treatment for
pre-existing vascular disease. Overall, development
of TTP was signiﬁcantly associated with collagen/
vascular conditions (14/37 cases, P<0.001). There
was also signiﬁcant association with severe sepsis and
the development of TTP (7/37 cases, P<0.005).
Clinical parameters
A range of clinical parameters available at time of
admission, are detailed in Table 3. Patients diagnosed
as having HUS had signiﬁcantly shorter hospital stays
[14 (¡1.5) days] than those with TTP [21 (¡3) days]
(P<0.02). Length of oliguria (deﬁned as urine output
<0.5 ml/kg per hour for 24 consecutive hours) was
signiﬁcantly associated with post-discharge or chronic
renal impairment (P=0.020) and this was true for
both HUS and TTP.
Treatment and outcomes
Patients with thrombotic microangiopathy were
assessed for treatment regimens employed and for
subsequent outcomes (Table 4). Treatment was not
standardized throughout Scotland but there was a
signiﬁcant association between HUS and use of
peritoneal dialysis (P=0.011). Other treatments for
HUS included plasma exchange, haemodialysis, haemo-
ﬁltration and steroid administration. Treatment for
Table 3. Univariate analysis of clinical markers for haemolytic uraemic syndrome (HUS) and thrombotic
thrombocytopaenic purpura (TTP)
Clinical markers HUS TTP P
Length of stay in hospital (days) 14¡1.5 21¡3 <0.02
Lactate dehydrogenase (LDH) 4864¡588 2411¡512 0.006
Serum albumin 27.4¡0.9 32.7¡1.7 0.017
C reactive protein (CRP) 56.3¡9.2 80¡25.4 0.305
Neutrophil count 14.9¡1.0 12.2¡1.2 0.238
White blood cell (WBC) count 19.8¡1.1 14¡1.1 0.021
Anuria (days) 10.4¡2.5 8.1¡1.6 0.692
Values are mean¡S.E.M. ; signiﬁcance relates to diﬀerence between thrombotic microangiopathy.
Table 4. Treatment regimens and outcomes for haemolytic uraemic syndrome (HUS) and thrombotic
thrombocytopaenic purpura (TTP)
Treatment HUS (n=73) TTP (n=37) P
Peritoneal dialysis 18 (25%) 0 (0%) 0.011
Plasma exchange 15 (21%) 30 (81%) <0.001
Steroid administration 6 (8%) 17 (46%) <0.001
Haemodialysis 16 (22%) 5 (14%) 0.333
Haemoﬁltration 3 (4%) 1 (3%) 0.464
Outcomes
Initial recovery/release home 59 (81%) 27 (73%) 0.219
Renal impairment 13 (35%) 6 (16%) 0.657
Dialysis dependence 7 (10%) 4 (11%) 0.974
Neurological impairment 1 (1%) 5 (14%) <0.001
Death 3 (4%) 5 (14%) 0.076
Signiﬁcance relates to diﬀerence between thrombotic microangiopathy.
TTP consisted of plasma exchange and/or steroid
administration and there was a strong association
with these particular methods of treatment and diag-
nosis of TTP (both P<0.001).
Of 110 patients diagnosed with thrombotic micro-
angiopathy, 86 were discharged directly to home
without dialysis. Eight patients died, while 19 patients
had some form of renal impairment on discharge,
with 11 of those 19 requiring long-term, post-
discharge dialysis. There was no association between
diagnosis of thrombotic microangiopathy and out-
come. Patients were followed up for up to 3 years
(K. G. J. Pollock, unpublished data).
DISCUSSION
Recent studies have contributed greatly to our current
understanding of the molecular mechanisms leading
to HUS and TTP [3, 13, 15]. However, prompt diag-
nosis and relevant therapy still remain challenging
because of the clinical similarities in these disorders.
The study sought to extend current knowledge by
monitoring all age groups with thrombotic micro-
angiopathies, as well as the extent of clinical pres-
entations of these disorders. This study provides a
range of data including epidemiology, demography,
clinical parameters, treatment regimens and out-
comes, and demonstrates that clinical surveillance
of thrombotic microangiopathies is an eﬃcient
and complementary approach to VTEC surveillance
(which includes E. coli O157). While children are
more likely to develop VTEC-associated HUS, cases
do occur in the adult population and the similarity
of presentation in adults and children with VTEC-
associated HUS was high, with most (90%) HUS
patients presenting with classic VTEC clinical features
of bloody diarrhoea and abdominal pain. Clinical
surveillance conﬁrms that VTEC remains the most
common cause of microangiopathy in Scotland and
reinforces the need to identify and treat cases of
VTEC sooner than we are managing to achieve at
present.
In contrast to the predisposing factors associated
with HUS (predominantly E. coli O157), patients
with TTP had diverse predisposing factors and/or
infections (particularly those with severe sepsis). The
symptoms preceding HUS or TTP were also quite
diﬀerent and this suggests that while TTP and HUS
share some features and on rare occasion can be
diﬃcult to distinguish, they are, in fact, two quite
diﬀerent entities with diﬀerent pathophysiologies.
This observation is in accordance with other studies
[11, 16]. Also, the majority of clinical markers and
treatments employed for the two syndromes are quite
distinct. For these reasons, we believe that the term
HUS/TTP is imprecise and should be abandoned
because current evidence indicates that TTP and HUS
diﬀer in pathogenesis and they do not encompass
all forms of thrombotic microangiopathies. When
the underlying cause of disease is uncertain, the
appellation thrombotic microangiopathy is suﬃcient,
appropriate and preferable.
HUS patients were routinely treated with perito-
neal dialysis or haemodialysis, although in some
instances, treatment involved only careful monitoring
and parenteral volume expansion. A recent study
encouraged the hospitalization of children infected
with E. coli O157 and administration of intravenous
isotonic ﬂuids, as soon as possible in illness, even
before microbiological culture results were known
[15]. This volume expansion was associated with
relative renal protection, as shown by the association
between parenteral volume expansion before the
development of HUS and attenuated renal injury
during HUS. Interestingly, children who present early
in illness during VTEC infections have higher rates
of developing HUS [17] possibly because they have
more severe or fulminant vascular injury. However,
infected children who seek medical attention early in
illness present a paradoxical opportunity: while they
are more likely to develop HUS, they also stand
to beneﬁt from an opportunity to receive prompt
hospital treatment well before renal damage ensues.
The potential value of recognizing, and volume
expanding such children early in illness should not be
overlooked.
Patients with TTP were routinely treated with
plasma exchange and/or steroids, as is common
practice in other centres [16, 17]. The mortality rate
from TTP has decreased signiﬁcantly since plasma
exchange was introduced [18, 19], although in our
cohort 14% of TTP cases did not respond to plasma
exchange and subsequently died. Measurement of
ADAMTS13 activity may be useful for early diag-
nosis, with severe ADAMTS13 deﬁciency appearing
to be speciﬁc for TTP [6]. In particular, the discrimi-
nation of TTP from HUS, especially in adults, can be
an urgent issue for treatment because most diarrhoea-
positive HUS cases are associated with VTEC. Recent
advances in assay methods should facilitate labora-
tory testing of ADAMTS13 for patients with throm-
botic microangiopathy. Ideally, all patients in the
study diagnosed with TTP would have had plasma
tested for ADAMTS13 levels to conﬁrm a diagnosis
of TTP but this was not feasible at all Scottish centres.
However, a clinical diagnosis of TTP has been
made in other studies without the beneﬁt of such
assays [20].
While the case deﬁnition for thrombotic micro-
angiopathy is sensitive and probably identiﬁes most
thrombotic microangiopathies in Scotland, one of the
main limitations of the study is the probable under-
reporting of cancer-associated TTP. Only one case
has been reported in 3 years and this probably rep-
resents a fraction of the actual numbers for several
reasons. Clinicians who specialize in this area are less
likely to report thrombotic microangiopathy, where
malignancy is terminal or highly advanced and would
also be less likely to seek consent for participation in
the study. We did not target such specialists and in
this respect, we may have biased the clinician sample.
One of the main confounding factors for the diagnosis
of TTP is age; speciﬁcally, patients with thrombotic
microangiopathy who are older are more likely to be
on anticoagulant therapy for vascular conditions or
have other chronic problems and this partly explains
the association between age and being diagnosed with
TTP caused by endothelial damage incurred over the
life experience.
Future surveillance and follow-up questionnaires in
this cohort could identify cases that recover initially
but subsequently develop occult nephropathy or
neurological problems. Follow-up studies have pro-
duced conﬂicting results with regard to renal outcome
after an episode of thrombotic microangiopathy
[21, 22]. Brandt and colleagues prospectively studied
a cohort of individuals following an outbreak of
VTEC-associated HUS in Washington State and
found that cholelithiasis and other gastrointestinal
sequelae were associated with HUS [21]. Further-
more, renal sequelae were identiﬁed in 35% of the
cohort but the follow-up period was limited to only
3 years and the short follow-up period may under-
estimate the extent and severity of eventual renal
sequelae. In a study looking at recovery after
diarrhoea-associated HUS, 31% of children had an
increased urinary albumin excretion, 18% had a
reduced glomerular ﬁltration rate and 10% had both,
in association with a higher systolic blood pressure,
indicating a signiﬁcant nephropathy in this group [23].
However, in the Scottish experience, the outcome
for children with VTEC-associated HUS is much
better than that quoted above and this corroborates
the outcome experience of international colleagues
[2, 3, 24]. Subsets of patients with HUS should be
particularly scrutinized for chronic renal sequelae
rates, particularly those in whom anuria occurs.
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